Cargando…

Identification of a CD8+ T-cell response to a predicted neoantigen in malignant mesothelioma

Neoantigens present unique and specific targets for personalized cancer immunotherapy strategies. Given the low mutational burden yet immunotherapy responsiveness of malignant mesothelioma (MM) when compared to other carcinogen-induced malignancies, identifying candidate neoantigens and T cells that...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sneddon, Sophie, Rive, Craig M., Ma, Shaokang, Dick, Ian M., Allcock, Richard J. N., Brown, Scott D., Holt, Robert A., Watson, Mark, Leary, Shay, Lee, Y. C. Gary, Robinson, Bruce W. S., Creaney, Jenette
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6959430/ https://www.ncbi.nlm.nih.gov/pubmed/32002298 http://dx.doi.org/10.1080/2162402X.2019.1684713

Ejemplares similares

Whole exome sequencing of an asbestos-induced wild-type murine model of malignant mesothelioma
por: Sneddon, Sophie, et al.
Publicado: (2017)

Discovery of new biomarkers for malignant mesothelioma
por: Creaney, Jenette, et al.
Publicado: (2015)

Strong spontaneous tumor neoantigen responses induced by a natural human carcinogen
por: Creaney, Jenette, et al.
Publicado: (2015)

What’s next in cancer immunotherapy? - The promise and challenges of neoantigen vaccination
por: Redwood, Alec J., et al.
Publicado: (2022)

Auto-Antibodies to β-F1-ATPase and Vimentin in Malignant Mesothelioma
por: Creaney, Jenette, et al.
Publicado: (2011)

Pleural Fluid Mesothelin as an Adjunct to the Diagnosis of Pleural Malignant Mesothelioma
por: Creaney, Jenette, et al.
Publicado: (2014)

Comparison of the Diagnostic Accuracy of the MSLN Gene Products, Mesothelin and Megakaryocyte Potentiating Factor, as Biomarkers for Mesothelioma in Pleural Effusions and Serum
por: Creaney, Jenette, et al.
Publicado: (2013)

Secreted primary human malignant mesothelioma exosome signature reflects oncogenic cargo
por: Greening, David W., et al.
Publicado: (2016)

Hyaluronic acid in viscous malignant mesothelioma pleural effusion
por: Cheah, Hui Min, et al.
Publicado: (2020)

Characterization of neoantigen-specific T cells in cancer resistant to immune checkpoint therapies
por: Li, Shamin, et al.
Publicado: (2021)

Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma
por: Creaney, Jenette, et al.
Publicado: (2014)

MicroRNA Signatures in Malignant Pleural Mesothelioma Effusions
por: Birnie, Kimberly A., et al.
Publicado: (2019)

How Our Continuing Studies of the Pre-clinical Inbred Mouse Models of Mesothelioma Have Influenced the Development of New Therapies
por: Robinson, Bruce W.S., et al.
Publicado: (2022)

Consistent gene expression profiles in MexTAg transgenic mouse and wild type mouse asbestos-induced mesothelioma
por: Robinson, Cleo, et al.
Publicado: (2015)

ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4–10 years in advance of clinical symptoms
por: Morré, D. James, et al.
Publicado: (2016)

Erratum to: ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4–10 years in advance of clinical symptoms
por: Morré, D. James, et al.
Publicado: (2016)

Pre-treatment tumor neo-antigen responses in draining lymph nodes are infrequent but predict checkpoint blockade therapy outcome
por: Ma, Shaokang, et al.
Publicado: (2019)

Comprehensive genomic and tumour immune profiling reveals potential therapeutic targets in malignant pleural mesothelioma
por: Creaney, Jenette, et al.
Publicado: (2022)

Chromosomal rearrangements and their neoantigenic potential in mesothelioma
por: Mansfield, Aaron Scott, et al.
Publicado: (2020)

Tumour associated lymphocytes in the pleural effusions of patients with mesothelioma express high levels of inhibitory receptors
por: Chee, Jonathan, et al.
Publicado: (2018)

Calretinin as a blood-based biomarker for mesothelioma
por: Johnen, Georg, et al.
Publicado: (2017)

Neutrophil-to-lymphocyte ratio in malignant pleural fluid: Prognostic significance
por: Popowicz, Natalia, et al.
Publicado: (2021)

Immune marker expression of irradiated mesothelioma cell lines
por: Chang, Faith, et al.
Publicado: (2022)

Overexpression and altered glycosylation of MUC1 in malignant mesothelioma
por: Creaney, J, et al.
Publicado: (2008)

Existing models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma
por: Meniawy, T M, et al.
Publicado: (2013)

Neoantigens in Hematologic Malignancies
por: Biernacki, Melinda A., et al.
Publicado: (2020)

Guidelines for cytopathologic diagnosis of epithelioid and mixed type malignant mesothelioma. Complementary statement from the International Mesothelioma Interest Group, also endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology
por: Hjerpe, Anders, et al.
Publicado: (2015)

Transient Treg depletion enhances therapeutic anti‐cancer vaccination
por: Fisher, Scott A., et al.
Publicado: (2016)

p53 autoantibodies in patients with malignant mesothelioma: stability through disease progression
por: Creaney, J, et al.
Publicado: (2001)

Profile of soluble factors in pleural effusions predict prognosis in mesothelioma
por: Dick, I.M., et al.
Publicado: (2022)

Mitochondria-derived reactive oxygen species drive GANT61-induced mesothelioma cell apoptosis
por: Lim, Chuan Bian, et al.
Publicado: (2015)

Response to comment on ‘Existing prognostic models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma'
por: Meniawy, T M, et al.
Publicado: (2014)

CD7 Expression in Malignant Pleural Mesothelioma
por: Hibi, Shigeyoshi, et al.
Publicado: (1992)

Randomised placebo-controlled cross-over study examining the role of anamorelin in mesothelioma (The ANTHEM study): rationale and protocol
por: Hoon, Siao Nge, et al.
Publicado: (2020)

Rapid selection and identification of functional CD8(+) T cell epitopes from large peptide-coding libraries
por: Sharma, Govinda, et al.
Publicado: (2019)

Association of Biomarker Levels with Severity of Asbestos-Related Diseases
por: Park, Eun-Kee, et al.
Publicado: (2012)

Neoantigens in Hematological Malignancies—Ultimate Targets for Immunotherapy?
por: Roerden, Malte, et al.
Publicado: (2019)

Genetic Variants Associated with Increased Risk of Malignant Pleural Mesothelioma: A Genome-Wide Association Study
por: Matullo, Giuseppe, et al.
Publicado: (2013)

Neoantigen characteristics in the context of the complete predicted MHC class I self-immunopeptidome
por: Brown, Scott D., et al.
Publicado: (2018)

Malignant mesothelioma
por: Ruffié, P, et al.
Publicado: (2001)

Cannot write session to /tmp/vufind_sessions/sess_m5er2tiu91nmbsrfei820jlr5c